Subscribe

Your FREE subscription will give you access to articles, research reports, Biopharma CEO Confidence quarterly reports and much more!

Strategic Sourcing Insights From Kineticos’ Trusted Sourcing Team

The strategic sourcing management experts at Kineticos deliver value to clients through the use of vast and varied experience and knowledge gained with an array sourcing initiatives in the life sciences industries. Below are case studies, white papers, and articles written by our expert sourcing team discussing notable subjects relating to strategic sourcing.

Click the Tabs Below for Strategic Sourcing Case Studies, White Papers & Articles, and Blog

 


Case Studies
Articles
Blog
  • Diagnostics Partnering Support

    Situation: An emerging oncology diagnostics company was in need of a Business Development strategy and retained Kineticos to develop such

     

    Read this Case Study

  • Voice of Customer Study

    Situation: A joint venture between two European companies was looking to maximize the commercial potential of its automated plate reader

     

    Read this Case Study

  • Go-To-Market Strategy

    Situation: As a follow up to a pricing study, Kineticos was retained by a specialty laboratory to develop a comprehensive

     

    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the

     

    Read this Case Study

  • Business Development & Licensing

    Situation: An innovative oncology diagnostics company retained Kineticos to assist in developing their pitch deck, as well as developing and

     

    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and

     

    Read this Case Study

  • Taking CAR-T Therapy to the Next Level

    Taking CAR-T Therapy to the Next Level is Part 2 of 3 of our most recent CAR-T series.  The dialogue

     

    Read this Article

  • CAR-T Therapy: Are We Getting a Bargain?

    With cancer research and treatment evolving so dramatically over the past 10 years, we’re left thinking what will the next

     

    Read this Article

  • Bridges and Barriers to Advancing CAR-T Therapy – Part 2

    In Part 1 of our discussion with Dr. Skolnik, Kineticos Operating Executive, Steve Buckanavage, explored how targeted combination therapies and

     

    Read this Article

  • Bridges and Barriers to Advancing CAR-T Therapy – Part 1

    One result of the Oncology explosion over the past 10 years has been the advent of CAR T therapy. In

     

    Read this Article

  • Ex-US Opportunities and Limitations

    Oncology Diagnostics Panel Session Ex-US Opportunities and Limitations explores the landscape outside of the US with a focus on larger

     

    Read this Article

  • The Value and Drawbacks of an Integrated Pharma/Diagnostics Model

    Oncology Diagnostics Panel Session The Value and Drawbacks of an Integrated Pharma/Diagnostics Model dives into how Roche has revolutionized an

     

    Read this Article

  • How Metrics Can Help Identify and Solve Operational Challenges

    Article Preview As the sophistication of operational practices across life sciences increases; unfortunately, so do the difficulty and complexity of

     

    Read this Blog Post

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Driving Revenue and EBIDTA at CROs through Customer Loyalty

    Article Preview Determining customer satisfaction and loyalty is a difficult endeavor for most businesses. Traditional voice of customer surveys are

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent

     

    Read this Blog Post

  • Next Generation Sequencing: Using Technology to Develop Mutually-Beneficial Partnerships

    Article Preview Arup Laboratories announced it will begin offering next-generation sequencing (NGS) based high resolution Human Leukocyte Antigen (HLA) genotyping

     

    Read this Blog Post


Contact Us Today to Discover How We Can Elevate Your Business Our Strategy Consulting Services Are Designed to Enhance Your Value

Contact Us Today
Top